Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
27. Dezember 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
Apricus Biosciences Receives Nasdaq Compliance Notice
01. Dezember 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences to Present at the 9th Annual LD Micro Main Event
29. November 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback
18. November 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results
08. November 2016 16:01 ET
|
Apricus Biosciences
Strategic Focus on Growing Global Vitaros® Revenue and Achieving Profitability in 2017Apricus Granted Type B Meeting with FDA to Discuss the Vitaros® U.S. NDA Re-SubmissionConference Call / Webcast...
Apricus Biosciences Announces Corporate Update and Third Quarter 2016 Financial Results Conference Call
02. November 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Greece
26. Oktober 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces 1-for-10 Reverse Stock Split
20. Oktober 2016 16:30 ET
|
Apricus Biosciences
SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced a...
Apricus Biosciences to Present at the 2016 BIO Investor Forum
12. Oktober 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Closes $3.7 Million Registered Direct Offering
28. September 2016 19:00 ET
|
Apricus Biosciences
SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...